nivolumab,ipilimumab
bms
['/ipi', 'nivo', 'nsclc', 'sclc', 'increase,(-increased)']
63% pcr rates after neoadjuvant nivo/ipi ccrt in t3-4 n0-2 nsclc (increase trial) #esmo. i wonder what the pcr rates would be after defintive immuno-chemo-radiotherpy.